Neuropeutics

Executive Summary

Neuropeutics is a preclinical-stage biotech company focused on developing novel peptide-based therapeutics for neurological disorders and pain management. Founded in 2019 and headquartered in San Diego, the company leverages its proprietary peptide platform to address high unmet needs in conditions such as chronic pain and neurodegenerative diseases. With a small, agile team, Neuropeutics aims to advance its lead candidates through IND-enabling studies, positioning itself for potential clinical development. However, the company remains in early stages with no disclosed funding rounds or partnerships, making its near-term progress uncertain.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Nomination60% success
• Q4 2026Preclinical Efficacy Data Release50% success
• H2 2026Series A Funding Announcement40% success